Treatment patterns and healthcare system burden of managed care patients with suspected pulmonary arterial hypertension in the United States

Journal of Medical Economics
Ronda CopherMaria Laura Monsalvo

Abstract

To describe treatment patterns and healthcare burden among individuals with suspected pulmonary arterial hypertension (PAH), as identified through a practice guideline-based healthcare claims algorithm. Adults with evidence of PAH from 1 January 2004 (commercial and Medicaid) or 1 July 2006 (Medicare Advantage) through 30 June 2008 were identified. Given the lack of an ICD-9 code for PAH, an algorithm was developed requiring: (1) ≥ 1 claim for PAH medication (index date); (2) ≥ 1 claim with a pulmonary hypertension diagnosis code in the 6-month pre-index period (baseline) or within 90 days post-index; (3) a right heart catheterization or pulmonary hypertension-related inpatient stay during baseline or within 90 days post-index; and (4) continuous health plan enrollment for 6 months pre-index and ≥ 6 months post-index. Patients with PAH-specific medications during baseline were excluded. Treatment patterns, healthcare utilization, and costs were assessed during the period ending with the earlier of health plan disenrollment or 31 December 2008. Among the 521 included patients, 69% were female. Most patients (94%) initiated treatment with monotherapy (most commonly sildenafil or bosentan), and 12.7% of all patients augmented thei...Continue Reading

References

Aug 1, 1987·Annals of Internal Medicine·S RichS K Koerner
Jul 14, 2004·Chest·Lewis J Rubin, UNKNOWN American College of Chest Physicians
Feb 4, 2006·American Journal of Respiratory and Critical Care Medicine·Marc HumbertGérald Simonneau
Mar 16, 2007·The European Respiratory Journal·A J PeacockS Stewart
Sep 7, 2007·The European Respiratory Journal·T ThenappanM Gomberg-Maitland
Feb 2, 2008·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Joyce A CramerPeter K Wong
Jul 9, 2009·Journal of the American College of Cardiology·Robyn J BarstNazzareno Galiè
Dec 25, 2009·The European Respiratory Journal·T ThenappanM Gomberg-Maitland
Jun 15, 2010·European Heart Journal·David MontaniOlivier Sitbon
Jul 29, 2011·Current Medical Research and Opinion·Noam Y KirsonTodd Williamson

❮ Previous
Next ❯

Citations

Oct 25, 2013·Science Translational Medicine·Gopinath Sutendra, Evangelos D Michelakis
Dec 30, 2014·BMC Health Services Research·Mirko SikiricaJesse Potash
Nov 26, 2013·Clinics in Chest Medicine·Meredith E PughIvan M Robbins
Dec 31, 2015·PharmacoEconomics·Shuyan GuHengjin Dong
Feb 27, 2018·Pulmonary Circulation·Ravikanth PapaniAlexander G Duarte
Jul 10, 2018·American Journal of Respiratory and Critical Care Medicine·Christopher J Mullin, Corey E Ventetuolo
Apr 16, 2019·Therapeutic Advances in Respiratory Disease·Kristin B HighlandWilliam Drake
Oct 9, 2019·Journal of Cardiovascular Pharmacology and Therapeutics·Shraddha NarechaniaAdriano R Tonelli
Mar 14, 2019·Annals of the American Thoracic Society·Stephen C MathaiCorey E Ventetuolo
Apr 13, 2017·BMC Pulmonary Medicine·Gustavo A HeresiJustin S Yu
Nov 30, 2019·BMC Pulmonary Medicine·Kathleen MorrisroeMandana Nikpour
Feb 24, 2021·Therapeutic Advances in Respiratory Disease·Fernando ExpostoAmélie Beaudet
Aug 18, 2021·The American Journal of Emergency Medicine·Susan R WilcoxCarlos A Camargo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.